Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Operating Lease Liabilities

Operating Lease Liabilities at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$2.03M+164%
Wave Life Sciences logo
Wave Life SciencesWVE
$40.08M+195%
Arrowhead Research logo
Arrowhead ResearchARWR
$100.11M-6.9%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$10.47M+32.7%
Maze Therapeutics logo
Maze TherapeuticsMAZE
$17.55M-17.0%
Delcath Systems logo
Delcath SystemsDCTH
$2.27M+158%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Gross profit$43.5M
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$4.3M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.79B+56.5%
Enterprise value$11.88B+58.8%
P/S9.2×-5.4×

Profitability

See full
Gross margin96.5%
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050845
Line itemJune 30,2026December 31,2025
Total current liabilities374,204310,288
Long term liabilities:
Loan payable, net of discount340,794339,881
Operating lease liabilities, net of current portion5,9236,731
Total long term liabilities346,717346,612
Total liabilities720,921656,900
Stockholders’ equity:
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2026 and December 31, 2025; 2,369,797 shares issued and outstanding at June 30, 2026 and December 31, 2025

Item 1. Financial Statements (Unaudited):

FAQ

What is Madrigal Pharmaceuticals, Inc.'s operating lease liabilities?
Madrigal Pharmaceuticals, Inc. (MDGL) reported operating lease liabilities of $5.92M in Q2 2026.
How has Madrigal Pharmaceuticals, Inc.'s operating lease liabilities changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s operating lease liabilities increased by 30.9% year-over-year, from $4.52M to $5.92M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s operating lease liabilities?
Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s operating lease liabilities has grown at a 70.4% compound annual growth rate (CAGR), from $468K to $6.73M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Madrigal Pharmaceuticals, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude